Next Article in Journal
Preparation of Magnetic Carbon Nanotubes (Mag-CNTs) for Biomedical and Biotechnological Applications
Next Article in Special Issue
Molecular Basis of Cardiac Myxomas
Previous Article in Journal
Characterization of a κ-Carrageenase from Marine Cellulophaga lytica strain N5-2 and Analysis of Its Degradation Products
Previous Article in Special Issue
Radiation-Sensitising Effects of Antennapedia Proteins (ANTP)-SmacN7 on Tumour Cells
Int. J. Mol. Sci. 2013, 14(12), 24603-24618; doi:10.3390/ijms141224603
Article

The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo

1
, 2,3
, 1
, 1
, 1
, 2,3
, 2,3
, 2,3,*  and 1,*
Received: 28 October 2013; in revised form: 21 November 2013 / Accepted: 4 December 2013 / Published: 18 December 2013
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
View Full-Text   |   Download PDF [2503 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Recent studies suggest that metformin, a widely used antidiabetic agent, may reduce cancer risk and improve prognosis of certain malignancies. However, the mechanisms for the anti-cancer effects of metformin remain uncertain. In this study, we investigated the effects of metformin on human bladder cancer cells and the underlying mechanisms. Metformin significantly inhibited the proliferation and colony formation of 5637 and T24 cells in vitro; specifically, metformin induced an apparent cell cycle arrest in G0/G1 phases, accompanied by a strong decrease of cyclin D1, cyclin-dependent kinase 4 (CDK4), E2F1 and an increase of p21waf-1. Further experiments revealed that metformin activated AMP-activated protein kinase (AMPK) and suppressed mammalian target of rapamycin (mTOR), the central regulator of protein synthesis and cell growth. Moreover, daily treatment of metformin led to a substantial inhibition of tumor growth in a xenograft model with concomitant decrease in the expression of proliferating cell nuclear antigen (PCNA), cyclin D1 and p-mTOR. The in vitro and in vivo results demonstrate that metformin efficiently suppresses the proliferation of bladder cancer cells and suggest that metformin may be a potential therapeutic agent for the treatment of bladder cancer.
Keywords: metformin; bladder cancer; cyclin D1; AMPK; mTOR metformin; bladder cancer; cyclin D1; AMPK; mTOR
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Zhang, T.; Guo, P.; Zhang, Y.; Xiong, H.; Yu, X.; Xu, S.; Wang, X.; He, D.; Jin, X. The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo. Int. J. Mol. Sci. 2013, 14, 24603-24618.

AMA Style

Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, Wang X, He D, Jin X. The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo. International Journal of Molecular Sciences. 2013; 14(12):24603-24618.

Chicago/Turabian Style

Zhang, Tao; Guo, Peng; Zhang, Yinan; Xiong, Hui; Yu, Xiao; Xu, Shan; Wang, Xinyang; He, Dalin; Jin, Xunbo. 2013. "The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo." Int. J. Mol. Sci. 14, no. 12: 24603-24618.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert